Industry News
Share your love
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
Alcon Signs $770 Million Deal to Acquire Aerie Pharma. I OBN
Swiss eye care company Alcon AG announced on Tuesday that it has entered into a definitive merger agreement with Aerie Pharmaceuticals (AERI.O) in a deal worth around $770 million. This deal complements Alcon’s dedication to the ophthalmic pharmaceutical industry and is…
Selagine and Grifols Team Up for DED Eye Drops
Selagine announced a global collaboration with Grifols to develop and commercialize immunoglobulin eye drops for dry eye disease. Financial terms of the agreement were not disclosed. As per the agreement, Selagine will receive an upfront payment and annual collaboration fee,…
Apotex Recalls Brimonidine Tartrate Ophthalmic Solution
Apotex Corp. has initiated a voluntary recall at the consumer level for 6 lots of brimonidine tartrate ophthalmic solution, 0.15%, distributed nationwide in the United States between April 5, 2022 to February 22, 2023 with the guidance of the US…
Akorn Pharmaceuticals Files for Bankruptcy
Akorn Pharmaceuticals, a maker of generic and branded drugs, has announced that it is ceasing operations business. The company, which provided over 20 ophthalmic products, has filed for chapter 7 bankruptcy, and will close all facilities in the United States. In…
M1 Molecule: A Promising Treatment for Optic Nerve Injury
Traumatic injury to the central nervous system (CNS), spinal cord, and optic nerve is the primary cause of disability and the second largest cause of mortality worldwide. CNS injuries frequently result in catastrophic loss of sensory, motor, and visual skills,…
HealthCare Royalty And Clearside Bio to Enter Into Agreement
Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. The money received from the deal will be put to use by Clearside to fund the ongoing clinical testing…
Topcon and OphtAI Collaborate for AI Technology
Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…
Frontera’s Trial for Retinitis Pigmentosa Kicks Off
Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…
FDA Issues Warning Letter to RightEye
The FDA issued a Warning Letter1 on January 31, 2023, to RightEye, LLC, the manufacturer of the RightEye Vision System, for misbranding and adulteration. The RightEye Vision System is a Class II Nystagmograph medical device that has been cleared “recording,…